Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.

被引：0
|
作者：
Vey, N
Dreyfus, F
Guerci, A
Fenaux, P
Dombret, H
Burnett, AK
Bosly, A
Feremans, W
Bowen, DT
Heiskala, M
机构：
[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales
[2] Clin Univ Mt Godinne, Yvoir, Belgium
[3] Erasme Univ Hosp, Brussels, Belgium
[4] Ninewells Hosp, Dundee DD1 9SY, Scotland
[5] Celll Therapeut Inc, Clin, Seattle, WA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1433
引用
收藏
页码：401A / 402A
页数：2
相关论文
共 50 条
  • [31] CHROMOSOMAL RESULTS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    LESSARD, M
    BRIZARD, A
    GUILHOT, F
    TANZER, J
    BLUT, 1988, 56 (06): : C9 - C9
  • [32] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [33] Results of phase II clinical study of lenalidomide in Japanese patients with myelodysplastic syndrome (MDS)
    Harada, H.
    Watanabe, M.
    Suzuki, K.
    Yanagita, S.
    Suzuki, T.
    Yoshida, Y.
    Kimura, A.
    Tsudo, M.
    Takatoku, M.
    Ozawa, K.
    LEUKEMIA RESEARCH, 2009, 33 : S123 - S123
  • [34] Quality of life in individuals with myelodysplastic syndromes (MDS): A descriptive study.
    Thomas, ML
    Zhang, J
    Greenberg, PL
    BLOOD, 1999, 94 (10) : 662A - 662A
  • [35] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [36] Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced Leukemias or Myelodysplastic syndromes (MDS)
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Cortes, Jorge
    Estrov, Zeev
    Boone, Patricia
    Stuart, Iain
    Westwood, Robert
    Green, Simon
    Chiao, Judy H.
    Plunkett, Willilam
    BLOOD, 2007, 110 (11) : 270A - 270A
  • [37] A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Held, Lauren A.
    Rizzieri, David
    Long, Gwynn D.
    Gockerman, Jon P.
    Diehl, Louis F.
    De Castro, Carlos M.
    Moore, Joseph O.
    Horwitz, Mitchell E.
    Chao, Nelson J.
    Gasparetto, Cristina
    CANCER INVESTIGATION, 2013, 31 (03) : 172 - 176
  • [38] Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Gargia-Manero, Guillermo
    Faderl, Stefan
    Ferrajoli, Alessandra
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 785 - 785
  • [39] A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Erba, Harry Paul
    Sobecks, Ronald
    Advani, Anjali
    Nichols, Julie
    Chan, Josephine
    Kalaycio, Matt
    BLOOD, 2006, 108 (11) : 754A - 754A
  • [40] Preliminary results of a phase II study of Amifostine for patients with myelodysplastic syndrome.
    deCastro, CM
    Gockerman, JP
    Moore, JO
    Hathorn, JW
    Hartung, C
    Misuraca, J
    BLOOD, 1997, 90 (10) : 4034 - 4034
12345